Table 2.

Association of variables with breakthrough infection

Variable		Relative risk (RR)	95% CI of RR
Age (years)	≤ 50	1.48	0.90–2.45
	51–65	0.86	0.56–1.31
	> 65	0.93	0.64–1.37
Sex	Male vs female	1.44	0.98–2.10
Vaccine type	BNT162b2	1.35	0.87–2.08
	mRNA-1273	0.74	0.48–1.15
Cancer type	Hematologic vs solid	1.63	1.03–2.57
On antineoplastic therapy at the time of vaccination	Yes vs No	2.73	1.71–4.34
Cancer subgroup	Breast	0.51	0.28–0.92
	Endocrine	0.42	0.10–1.69
	Gastrointestinal	1.17	0.63–2.18
	Genitourinary—female reproductive	1.91	0.94–3.91
	Genitourinary—male reproductive	1.01	0.49–2.07
	Genitourinary—unspecified male/female	1.31	0.61–2.81
	Head and neck	0.26	0.04–1.86
	Leukemia	1.06	0.47–2.41
	Lymphoma	0.94	0.44–2.06
	Multiple myeloma	2.96	1.64–5.36
	Respiratory	0.89	0.36–2.17
	Skin	1.21	0.69–2.12
	Unspecified	2.25	0.32–15.76

 Bolded rows represent variables for which the 95% CI for RR does not cross 1.0